Erratum: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial ...
SEER-Medicare analyses across 2005–2007, 2010–2012, and 2017–2019 showed persistently lower adjusted curative-treatment rates for Black vs White beneficiaries with early-stage NSCLC (all P<.001).
SEER–Medicare analysis showed persistent adjusted racial gaps in curative-intent treatment for early-stage NSCLC, with Black patients less likely to receive surgery or radiotherapy across 2005–2019.
The researchers found that lower rates of curative treatment among Black patients versus White patients are driven by lack of receipt of surgical treatment. HealthDay News — Racial disparities persist ...
Hosted on MSN
Racial disparities persist in curative treatment for early-stage non-small cell lung cancer
TUESDAY, March 10, 2026 (HealthDay News) -- Racial disparities persist in receipt of curative treatment for early-stage non-small cell lung cancer (NSCLC), according to a study published online March ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results